Approximation to the Patient with Tumor of Unknown Origin
Journal Title: Journal of Integrative Oncology - Year 2017, Vol 6, Issue 2
Abstract
The tumor of unknown origin constitutes 3-7% of the cancers studied and is one of the 10 most frequent cancer diagnoses. It is a malignant tumor whose first origin or identification is not done in the clinical history, in the clinical exploration or in the complementary studies. At present, the effort in the primary search for the origin of the cancer that will be directed at specifying these entities and recognizing them as soon as possible is arduous. Today we have several techniques among which we highlight immunohistochemistry, molecular biology and radiodiagnosis that greatly facilitate the work of the clinician in detecting the origin of tumors, although none of them is conclusive.
Authors and Affiliations
Jesús Cobo Molinos, Antonio Cobo Molinos
Keywords
Related Articles
- EP ID EP348506
- DOI 10.4172/2329-6771.1000190
- Views 74
- Downloads 0
Febrile Neutropenia Risk with Adjuvant Docetaxel and Cyclophosphamide (TC) Chemotherapy Regimen in Two Brazilians Cancer Centers
Introduction: In selected patients diagnosed with Breast Cancer (BC), adjuvant chemotherapy might reduce local and systemic recurrence risk, as well as cancer death rate. The combination of Docetaxel and Cyclophosphamide...
Reiki Therapy is Credible in Oncology. A Possible Analysis...
In an earlier article by the author, the effectiveness and efficacy of Reiki Therapy when used as complementary therapy in patients with blood cancer was demonstrated. With the present article, the author invites readers...
The Chernobyl and It’s Long Term Consequence: Clinical Cases of Leukemia
The Chernobyl accident that occurred 30 years ago was one of the worst nuclear disasters ever. Although it’s effects have been the subject of several articles, the role of its repercussions in the etiology of hematologic...
Statistical Tool in Integrated Oncology: Propensity Score Methods
Randomized controlled trials are viewed as the “gold” standard study designs to generate evidence on effectiveness of interventions. In some situations in which randomized experiments are not possible, or not ethical, or...
Surveillance of Healthcare-Associated Infections Rates in Hematology-Oncology Patients
Background: Healthcare-associated infections (HAIs) consist of a major cause of morbidity and mortality among patients with hematologic malignancies, resulting in high length of stay and healthcare costs. The aim of this...